Lu sur http://onlinelibrary.wiley.com/wol1/doi ... 5/abstract
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis
Jorge Enrique Machado-Alba MD, PhD1,*, Luis Felipe Calvo-Torres MD1,2, Andrés Gaviria-Mendoza MD1 andCésar Augusto MejíA-Vélez MD1
Version of Record online: 23 MAR 2017 DOI: 10.1002/mus.25625
We determined the pyridostigmine prescription pattern in a population of patients with myasthenia gravis (MG).
A descriptive cross-sectional study was conducted by using a prescription database of 3.5 million individuals from which patients who had been diagnosed with MG and for whom pyridostigmine had been prescribed were selected.
A total of 306 outpatients with MG were found, and 258 were receiving pyridostigmine (mean age 53.0 ± 18.0 years). The calculated prevalence of MG was 86.7 cases per million persons. Monotherapy was used by 53.1% of the patients, prednisolone was used by 21.7%, and 30.2% used other immunomodulators. Medications for other comorbidities were taken by 74.8% of the patients, and 43.4% had prescriptions that could potentially trigger worsening symptoms.
Pyridostigmine is being prescribed at doses close to the defined daily doses predominantly as monotherapy. A high proportion of patients were also prescribed a medication that could aggravate their condition, including some that can trigger a myasthenic crisis